Search results
Results from the WOW.Com Content Network
JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP).
As lipid-lowering medications, statins are effective in lowering LDL cholesterol; they are widely used for primary prevention in people at high risk of cardiovascular disease, as well as in secondary prevention for those who have developed cardiovascular disease. [2][3][4] Side effects of statins include muscle pain, increased risk of diabetes ...
Atorvastatin has been associated with a small increase in fasting blood glucose levels over a 2-year period, particularly in patients with Type 2 Diabetes, however evidence is conflicting and clinical significance of this increase has not been determined. [69] [70] [71] Regular blood glucose monitoring may be advised in patients with Type 2 ...
Statins also increase the risk of developing type 2 diabetes. However, when you use healthy lifestyle changes to bring down cholesterol, all you get are the benefits—including a significant drop ...
Of the diabetes drugs prescribed off-label for weight loss, metformin is one of the most well-researched. If you have obesity or are struggling to lose weight, talk to a healthcare provider about ...
Statins may improve quality of life when used in people without existing cardiovascular disease (i.e. for primary prevention). [74] Statins decrease cholesterol in children with hypercholesterolemia, but no studies as of 2010 show improved outcomes [76] and diet is the mainstay of therapy in childhood. [39]
A small increased risk of raised blood sugar levels and the development of type 2 diabetes have been reported with the use of statins. A 2010 published meta-analysis found for every 255 patients taking a statin for 4 years, one additional case of diabetes would occur whilst preventing 5.4 major coronary events. [27]
HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, official symbol HMGCR) is the rate-controlling enzyme (NADH-dependent, EC 1.1.1.88; NADPH-dependent, EC 1.1.1.34) of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids. HMGCR catalyzes the conversion of HMG-CoA to mevalonic acid, a ...